Recent Company News

• 04:10 AM ET Aug 24, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:48 AM ET Nov 09, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:04 AM ET Nov 09, 2026
  

  Valneva announces positive Phase 2 results for tetravalent shigella vaccine candidate S4V2 (€2.50, 0.00)

• 01:00 AM ET Nov 09, 2026
  

  Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2

• 08:31 PM ET Nov 06, 2026
  

  The Technical Signals Behind (VALN) That Institutions Follow

• 11:45 AM ET Nov 04, 2026
  

  Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026

• 08:58 PM ET Oct 27, 2026
  

  (VALN) Risk Channels and Responsive Allocation

• 04:02 PM ET Oct 07, 2026
  

  Valneva provides update on IXCHIQ in UK (€2.61, 0.00)